North America Imaging Agents Market size exceeded USD 3.3 billion in 2021 and is expected to witness 4.7% CAGR from 2022 to 2028. Increasing number of cardiovascular and cancer cases will drive the market expansion. Heart condition refers to a number of circumstances that might affect heart from blood-vessel diseases to genetic defects. Around every forty seconds an American is expected to have a heart attack. Therefore, increasing number of heart conditions will favour the industry progression.

Get more details on this report - Request Free Sample PDF

Further, surging smoking and tobacco consumption has resulted in rise in number of lung cancer in the U.S. According to the Centers for Disease Control and Prevention (CDC), 2020 records, 12.5% or 30.8 million adults in the U.S. smoke cigarettes. This increases the rate of cancer every year leading to more health aliments.

North America Imaging Agents Market, By Product Type

The gadolinium-based contrast media segment accounted for USD 458 million revenue in 2021, attributed to rising usage of magnetic resonance imaging (MRI) to create detailed images of various organs and tissues in the body. Increasing prevalence of brain tumours, multiple sclerosis, traumatic brain injury, stroke, epilepsy has increased the demand for gadolinium-based contrast media. Similarly, growing number of long-term chronic diseases, as well as technological advancements will impel the market growth.

North America Market, By Application

Get more details on this report - Request Free Sample PDF

The oncology segment revenue in the North America imaging agents market was around USD 894.4 million in 2021, owing to rising prevalence of colorectal cancer and increasing levels of geriatric population base across North America. Colorectal cancer is the second leading cause of cancer deaths in developed economies. Colorectal cancer is diagnosed using a variety of imaging techniques, including computed tomography colonography (CTC) and optical colonoscopy.

North America Market, By Modality

The computed tomography (CT) segment dominated over 26% North America imaging agents market share in 2021. CT scan mainly produces images of the internal body parts such as bones, tissues, and organs. CT scan is beneficial for surgery, biopsy, and radiotherapy procedures and for the detection of internal injuries or internal bleeding in the body.  It also helps in detecting the location of tumor, infection, or blood clot. Surging adoption of optical colonoscopy and computed tomography colonography (CTC), for colorectal cancer diagnosis is anticipated to drive the industry growth.

North America Market, By End-use

The diagnostics and imaging centres segment crossed USD 915 million revenue in 2021, due to increasing awareness about cardiovascular disease treatment. The diagnostics and imaging centers usually encompass technologies such as X-rays, ultrasonography, computed tomography (CT) that are used for diagnosis, treatment planning, and prevention of chronic disorder will further spur the market size.

North America Market, By Country

The U.S. imaging agents market will observe around 4.5% growth rate during the forecast period. The companies are focusing on research and development activities and tends to focus on the funding. Several other participants inclining towards developing technological and innovative imaging agents for better results and expanding business in the market.  In addition, highly developed healthcare facilities with the presence of radiologist expert and surgeons in this country have boosted the market revenue.

Competitive Industry Landscape

Some of the leading companies operating in the North America imaging agents market include Trivitron Healthcare, Guerbet Group, Bracco Diagnostics, Inc., Eli Lily, GE Healthcare, Bayer Healthcare Pharmaceuticals, Aytu BioScience, Inc., Curium, and Lantheus Medical Imaging, Inc.

These companies have adopted different strategies such as launch of new products with technological advancements that have helped them in sustaining the market competition and gain significant position. For instance, in May 2020, Eli Lilly and Company subsidiary Avid Radiopharmaceuticals, Inc., received U.S. Food and Drug Administration approval for its positron emission tomography (PET) imaging agent, AMYVID and TAUVID. This helped the firm to strengthen its offerings and enhance company’s revenue generation.